Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Coating to Optimize Aneurysm Treatment In The New Flow Diverter Generation

NCT: NCT04870047 · COMPLETED

NCT IDNCT04870047
StatusCOMPLETED
Start Date2021-09-03
Completion2025-12-12
SponsorPhenox GmbH (INDUSTRY)
First posted
Last updated

Brief Summary

To assess safety and efficacy of p64 MW HPC Flow Modulation Device under single antiplatelet therapy compared to p64 MW Flow Modulation Device under dual antiplatelet therapy.

Frequently Asked Questions

What is Coating to Optimize Aneurysm Treatment In The New Flow Diverter Generation?

Coating to Optimize Aneurysm Treatment In The New Flow Diverter Generation is a clinical trial registered under NCT04870047. Current status: COMPLETED.

What is the status of NCT04870047?

The current status of NCT04870047 (Coating to Optimize Aneurysm Treatment In The New Flow Diverter Generation) is: COMPLETED.

When did Coating to Optimize Aneurysm Treatment In The New Flow Diverter Generation start?

Coating to Optimize Aneurysm Treatment In The New Flow Diverter Generation started on 2021-09-03.

Related Devices

K191687pORTAL Steerable Hydrophilic Guidewire and pORTAL EXT Extension WirePhenox Limited K221279pNOVUS 21 MicrocatheterPhenox, Ltd. K222848pRESET Thrombectomy DevicePhenox Limited K231539pRESET LITE Thrombectomy DevicePhenox Limited K242420pNOVUS 21 MicrocatheterPhenox, Ltd.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑